Job Description
Postdoctoral positions in the field of cancer pharmacogenomics are available immediately in Dr. Xifeng Wu’s lab at The University of Texas MD Anderson Cancer Center. Fellows are being recruited for projects aimed at identifying biomarkers for the prediction of cancer treatment outcomes by integrating genetic variation information with clinical and epidemiological data utilizing our well-characterized patient populations and extensive collection of biospecimens. Dr. Wu’s research group successfully executes contemporary epidemiologic strategies across the cancer continuum by employing advanced, state-of-the-art equipment including high- and mid-throughput assay platforms for genotyping, copy number analysis, next-generation sequencing, whole-genome expression profiling, as well as microRNA and metabolome profiling. Our capabilities include single-cell and high-content analysis, FISH, telomere length and mitochondrial DNA analysis, and other cell-based phenotypic studies.
The overarching goal of Dr. Wu’s translational research program is to construct comprehensive, clinically applicable risk prediction models along the entire cancer continuum, from etiology to screening, prognosis, treatment response and survivorship. To accomplish the program’s objectives, my laboratory practices multidisciplinary research that bridges the fields of basic science, epidemiology, biostatistics, and clinical research. We devise integrative strategies that enable risk assessment, early detection and delineation of early- and late-stage clinical outcomes. Our investigations channel towards identification and validation of clinically useful prognostic and predictive biomarkers, and discovery of molecular targets with therapeutic potential. Assimilation of biomarkers with epidemiological, clinical, phenotypic, and genetic information enables development of accurate and reliable personalized cancer risk prediction models that inform clinical care and empower clinical risk stratification along the cancer care continuum. Our multifaceted and highly innovative research has yielded novel and significant findings across malignancies, including in bladder cancer, lung cancer, renal cell carcinoma, and gastrointestinal cancer.
Successful applicants will have great opportunities to collaborate with an interdisciplinary team of biologists, epidemiologists, statisticians, and clinicians, and to develop multidisciplinary knowledge and techniques in molecular and cellular biology, epidemiology, statistics, genetics, genomics, and cancer medicine.
We seek highly motivated, enthusiastic individuals who have a Ph.D. and/or M.D. degree with less than 2 years of postdoctoral experience in biochemistry, molecular biology, cellular biology, genetics, or related fields. Applications, including curriculum vitae, contact information for three references, and a brief summary of past accomplishments should be sent by regular mail or email to: Shirley Freeman, Department of Epidemiology, Division of Cancer Prevention, The University of Texas MD Anderson Cancer Center, 1155 Pressler Blvd. Box 1340, Houston, TX, 77030. Email: SMFreeman1@mdanderson.org
M. D. Anderson Cancer Center is an equal opportunity employer and does not discriminate on basis of race, color, national origin, gender, sexual orientation, age, religion, disability or veteran status except where such distinction is required by law. All positions at The University of Texas M. D. Anderson Cancer Center are security sensitive and subject to examination of criminal history record information. Smoke-free and drug-free environment.
Contact: Shirley Freeman
Epidemiology
The University of Texas M. D. Anderson Cancer Center
1155 Pressler Blvd.
Houston, TX 77030
United States
Email: smfreeman1mdanderson.org
Employer's Web Site: Visit employer's website
得克萨斯大学MD安德森癌症中心
职位名称：癌症药理学博士后
招聘人数：4014855
发布日期：2014年9月2日
报名截止日期：不限满为止
职位描述
在肿瘤药物基因组学领域的博士后职位，立即可在西峰吴博士的实验室在得克萨斯大学MD安德森癌症中心的大学。研究员正在招募，旨在确定生物标记用于癌症治疗结果的预测与临床和流行病学资料利用我们良好的特点的患者人群和生物标本的广泛收集整合的遗传变异信息的项目。吴博士的研究小组采用先进设备，最先进的先进设备，包括高，中通量检测平台，用于基因分型成功执行过癌症连续当代流行病学策略，拷贝数分析，新一代测序，全基因组表达谱，以及小分子RNA和代谢组分析。我们的能力，包括单细胞和高内涵分析，FISH，端粒长度和线粒体DNA的分析，和其它细胞系的表型的研究。
吴医生的翻译研究项目的总体目标是建设综合性，临床应用风险预测模型在整个癌症连续，从病因学筛查，预后，治疗反应和存活率。为了实现该计划的目标，我的实验室实行多学科研究的桥梁基础科学，流行病学，生物统计学和临床研究领域。我们制定综合战略，使风险评估的早期和晚期阶段的临床结果，及早发现和圈定。我们的研究引向鉴定和临床价值的诊断和预测生物标记物验证和发现的分子靶标具有治疗潜力。生物标志物与流行病学，临床，表型和遗传信息的同化使的告知临床护理和授权以及癌症治疗的临床连续危险分层准确而可靠的个性化癌症风险预测模型的发展。我们的多面性和高度创新的研究已经跨越恶性肿瘤产生新颖显著发现，包括膀胱癌，肺癌，肾癌和胃肠道癌症。
成功的申请者将有很大的机会，生物学家，流行病学家，统计学家和临床医生组成的跨学科团队合作，发展的分子和细胞生物学，流行病学，统计学，遗传学，基因组学和癌症医学多学科的知识和技巧。
我们寻求积极进取，热心人士谁拥有博士学位和/或MD学位与不到2年的生物化学博士后经历，分子生物学，细胞生物学，遗传学，或相关领域。应用，包括个人简历，联系方式为三个引用，和过去的成就进行了简要总结应该通过普通邮件或电子邮件发送到：雪莉·弗里曼，流行病学研究室，癌症预防，得克萨斯大学MD安德森癌症中心的大学部， 1155普雷斯勒大道。盒1340，休斯敦，得克萨斯州，77030.电子邮件：SMFreeman1@mdanderson.org
MD安德森癌症中心是一个机会均等的雇主，基于种族，肤色，国籍，性别，性倾向，年龄，宗教，残疾或退伍军人身份的基础不歧视，除非这种区分法律要求。在得克萨斯大学MD安德森癌症中心的大学所有的位置都是检查犯罪记录的信息安全敏感的话题。无烟和无毒环保。
联系方式：雪莉·弗里曼
流行病学
得克萨斯大学MD安德森癌症中心的大学
1155普雷斯勒大道。
休斯顿，德克萨斯州77030
美国
电子邮件：smfreeman1@mdanderson.org
中国-博士人才网发布
